News & Updates
Filter by Specialty:
Vonoprazan-amoxicillin on par with quadruple therapy for H pylori eradication
Dual therapy with vonoprazan and amoxicillin (VA-dual) for 10 days results in a 90.8-percent eradication rate of Helicobacter pylori (H pylori) and fewer adverse events (AEs) compared with the standard 14-day bismuth-based quadruple therapy (B-quadruple), a study has shown.
Vonoprazan-amoxicillin on par with quadruple therapy for H pylori eradication
09 May 2024Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir
Treating COVID-19 patients who had been vaccinated or did not have risk factors for severe disease with ritonavir-boosted nirmatrelvir (nirmatrelvir–ritonavir) did not expedite the time to symptom alleviation, reported investigators in the EPIC-SR trial.
Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir
30 Apr 2024Supplement cocktail boosts COVID-19 treatment arsenal
Daily supplementation with melatonin, zinc, and multivitamins cuts the duration of COVID-19 or COVID-19-like symptoms, thus supplementing the COVID-19 treatment armamentarium, a study has shown.
Supplement cocktail boosts COVID-19 treatment arsenal
29 Apr 2024Vertical COVID-19 transmission low in SG
Transmission of SARS-CoV-2 infection from mothers to newborns appears to be rare in a cohort study conducted by the KK Women’s and Children’s Hospital (KKH), Singapore General Hospital (SGH), and National University Hospital (NUH).
Vertical COVID-19 transmission low in SG
26 Apr 2024Otitis media cases in China require more attention
A recent systematic review and meta-analysis reveals a considerable burden of otitis media (OM) in China that is often overlooked. At present, the most common bacterial pathogen identified is Streptococcus pneumoniae (S pneumoniae).